Results 71 to 80 of about 26,042 (243)
Effects of Static and Low‐Frequency Magnetic Fields on Gene Expression
Journal of Magnetic Resonance Imaging, Volume 62, Issue 2, Page 317-334, August 2025.Substantial research over the past two decades has established that magnetic fields affect fundamental cellular processes, including gene expression. However, since biological cells and subcellular components exhibit diamagnetic behavior and are therefore subjected to very small magnetic forces that cannot directly compete with the viscoelastic and ...
Vitalii Zablotskii +3 more
wiley +1 more source
Imatinib resistance: diagnostic and therapeutic choices
Clinical Management Issues, 2015 We report a case of a 42-year-old woman with t(9;22) positive chronic myeloid leukemia (CML) who developed a sub-optimal response to therapy with imatinib mesylate due to M351T mutation and low plasma level of imatinib. Dose increase of imatinib resulted
Marianna De Muro +3 more
doaj +1 more source
Small Science, Volume 5, Issue 8, August 2025.Hyaluronic acid‐decorated imatinib‐loaded liposomes are developed to specific target CD44 receptor expressed by interstitial lung fibrosis cells, demonstrating higher uptake than empty liposomes. Based on promising in vitro data, they are administered intratracheally and intraperitoneally in a mouse bleomycin model, assessing their ability to decrease ...
Sara Bozzini +13 more
wiley +1 more source
Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS [PDF]
, 2011 The LC-ESI-MS was developed and validated for the analysis of imatinib in plasma and bone marrow samples using deuterated imatinib (D(8)-IM) as an internal standard. The biological samples were extracted using Strata-X-C SPE cartridges and separated on C&
Elliott, M. +4 more
core +1 more source
Imatinib-mesylate for all patients with hypereosinophilic syndrome? [PDF]
, 2004 Some recent papers have focused on the activity of imatinib-mesylate, a selective inhibitor of tyrosine kinase, in idiopathic hypereosinophilic syndrome (HES) [1], [2], [3] and [4].
Carella, A +5 more
core +1 more source
Journal of Veterinary Internal Medicine, Volume 39, Issue 4, July/August 2025.ABSTRACT A 21‐year‐old miniature donkey gelding was evaluated for pruritus, inappetence, hypertriglyceridemia, and alopecia of 2 weeks' duration. Hematology showed moderate eosinophilia, severe hypertriglyceridemia, and moderately increased liver enzyme activities. Cytologic evaluation of peritoneal fluid identified an eosinophilic transudate.
Carla K. Enriquez +4 more
wiley +1 more source
XML Evaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia
Iranian Journal of Blood and Cancer, 2016 Background: Imatinib mesylate is the first generation of Tyrosine kinase inhibitors (TKI) and highly effective in the treatment of chronic myeloid leukemia (CML).
Abolghasem Allahyari +3 more
doaj
Imatinib and hypophosphatemia: Case report and review of literature
Journal of Oncological Sciences, 2017 Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated.
Erdem Şen, İrem Öner, Özlem Ata
doaj +1 more source
V559A and N822I double KIT mutant melanoma with predictable response to imatinib? [PDF]
, 2011 Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/88125/1/j.1755-148X.2010.00822.x ...
Betz, Bryan +3 more
core +1 more source
The teratogenic effects of imatinib mesylate on rat fetuses
Toxicology Reports, 2015 Imatinib mesylate, a selective tyrosine kinase inhibitor, is the first line treatment against chronic myelogenous leukemia and gastrointestinal stromal tumors.
M.M. El Gendy +3 more
doaj +1 more source